Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFH375 Monotherapy and Combination Therapy in Advanced NSCLC With KRAS G12D Mutation
NCT07554859Phase 2Not yet recruiting
- Sponsor
- GenFleet Therapeutics
- Start
- May 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of GFH375 in non-small cell lung cancer (NSCLC) (3 arms), sponsored by GenFleet Therapeutics. Primary endpoint: Progression-Free Survival up to 24 months. Planned start May 2026; status: not yet recruiting.
02
Drugs
GFH375
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07554859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07554859.